Chronic heart failure is a common disease. It is also a serious disease with a mortality of
50% at 5 years, representing a significant cost in terms of public health expenditure.
Heart transplantation represents the "gold standard" of care for terminal heart failure
patients reached the end of the disease despite optimal medical and surgical management of
their disease, with a survival rate of transplant patients by 90% at 1 year and 82% at 3
Long term LVAD are an innovative technology available for more than a decade, developed in
part because of the shortage of cardiac grafts and high mortality among patients waiting for
transplants due to an important pending.
This technique is used substantially only for ten to fifteen years in the world. Survival
after implantation of latest devices reaches 80% at 1 year.
In France, this technique is intended for patients with terminal heart failure who ended
different pharmacological and invasive therapeutic resources available.
Currently, academic centers that offer the possibility of long-term LVAD support are
organized unicentric in order to centralize specialized care for these patients.
Indeed, patients candidates for the establishment of a long-term LVAD are rigorously selected
to ensure an acceptable survival.
However, practices vary considerably from one center to another in particular regarding:
- Implantation indications,
- Pre-implantation patient assessment,
- Implementation of pharmacological treatments, particularly anticoagulants or